BIOCARDIA INC (BCDA)
US09060U5074 - Common Stock
BioCardia’s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes
SUNNYVALE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ: BCDA), a developer of cellular and cell-derived therapeutics for the...
BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort
Call Scheduled for Study Clinical Leadership to Discuss Results and Details on Pivotal Randomized Trial...
BCDA Stock Earnings: BioCardia Beats EPS, Misses Revenue for Q4 2023
BCDA stock results show that BioCardia beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.
BCDA Stock Earnings: BioCardia Beats EPS, Misses Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips BioCardia (NASDAQ:BCDA) just reported results for the fourth quarter of 2023.Bi...
BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results
BioCardia®, Inc. today reported financial results for the year ended December 31, 2023 ...
BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024
BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024...
BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership
BioCardia & StemCardia biotechnology company partnership targets heart failure, the leading cause of death and a condition with limited treatment options...
BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study
Centers for Medicare & Medicaid Services (CMS) approves reimbursement coverage of the confirmatory Phase III clinical trial of CardiAMP heart failure...
BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure
CardiAMP cell therapy-treated patients had 37% relative risk reduction in heart death equivalent (death, heart transplant, left ventricular assist device...
BioCardia to sell 3.02M shares for holders (NASDAQ:BCDA)
BioCardia (BCDA) files prospectus for resale of 3.02M shares of common stock by selling stockholders. Not an offer to sell securities.
BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA
SUNNYVALE, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (“BioCardia” or the “Company”) (Nasdaq: BCDA), a biotechnology company focused on...
BioCardia Biotherapeutic Delivery and Morph Access Innovations Business Development Update for Shareholders
SUNNYVALE, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (Nasdaq: BCDA), a developer of cellular and cell-derived therapeutics for the...
BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction
SUNNYVALE, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the...
BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes
SUNNYVALE, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the...
BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval
SUNNYVALE, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the...
BioCardia's shares fall on discounted offering of its common stock (NASDAQ:BCDA)
BioCardia has entered into a deal for the purchase and sale of 2M shares at $0.65 per share, expecting gross proceeds of $1.3M for general corporate purposes.
BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules
SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived...
BioCardia stock jumps premarket as FDA approves heart failure trial (NASDAQ:BCDA)
BioCardia (BCDA) receives FDA approval for Phase 3 clinical trial of CardiAMP autologous cell therapy for ischemic heart failure, showing promising clinical...
BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure
SUNNYVALE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the...
BioCardia Reports Third Quarter 2023 Business Highlights and Financial Results
SUNNYVALE, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the...